Booster Therapeutics
Germany
- Berlin
- 11/10/2024
- Seed
- $15,000,000
Booster Therapeutics is pioneering a new class of medicines that activate proteasomes (the cell’s natural quality control machinery) to treat a range of complex indications. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function.
- Industry Biotechnology Research
- Website https://www.boostertx.com/
- LinkedIn https://www.linkedin.com/company/booster-therapeutics/
Related People
Diogo R. FelecianoCo Founder
Germany -
Berlin, Berlin
My mission is to revolutionize patient health by spearheading the development of game-changing and innovative treatments.
In 2020, founded Booster Therapeutics with the aim of discovering and developing a new class of drugs that can potentially treat various diseases where conventional treatment options fall short.
With over a decade of expertise in life sciences acquired through academic research, venture capital, and biotech, I have specialized knowledge in R&D, company building, and aging/neuro/ocular biology.
Bluprynt | $4,250,000 | (Feb 27, 2026)
UpGuard | $75,000,000 | (Feb 27, 2026)
Revel(US) | $150,000,000 | (Feb 27, 2026)
Alpa | $3,500,000 | (Feb 27, 2026)
ElastixAI | $18,000,000 | (Feb 27, 2026)
Callosum | $10,250,000 | (Feb 27, 2026)
JetScale AI | $5,400,000 | (Feb 27, 2026)
Dots | $8,900,000 | (Feb 27, 2026)
VITURE | $100,000,000 | (Feb 27, 2026)
Ark Climate | $2,478,315 | (Feb 27, 2026)
Jest | $7,000,000 | (Feb 27, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)